Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset TLRY

Coverage 92,268 Raw stories ingested 7,951 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,727 Assets with fetched stories

Cryptocurrencies BTC 4,245 ETH 3,075 SOL 1,750 XRP 1,686 USDC 965 HYPE 822

Stocks SPCX 879 MU 723 NVDA 684 MSFT 557 GOOGL 531 TSLA 504

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 147 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,679 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 31s ago
FMP Forex News Fetch every 5 min 4m ago
CoinGecko News Fetch every 5 min 4m ago
FIO Stock News Fetch every 10 min 8m ago
Patria Stock News Fetch every 10 min 8m ago
Editorial rewrite Rewrite every minute 31s ago
Asset sync Assets every 1 hour 28m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-23 11:48 2d ago Published 2026-07-23 07:00 2d ago	Tilray uvádí v Kanadě THC sáčky ZONNA Tilray Brands uvedla ZONNA, novou značku THC sáčků s rychlým účinkem pro dospělé uživatele v Kanadě. Každý sáček obsahuje 10 mg THC. TLRY Tilray	FMP Stock News	78
Original source text TORONTO, July 23, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, wellness, and beverage industries, today announced the launch of ZONNA, a new cannabis brand introducing fast-acting THC pouches designed for adult consumers seeking a discreet, smoke-free, and convenient cannabis experience. Launching with Bubble Pink, ZONNA combines innovative Capsoil™ technology with a portable pouch design to deliver a fast-acting experience. Designed to fit comfortably between the gum and lip, the compact pouches offer a discreet and odor-free alternative to traditional cannabis consumption methods. Blair MacNeil, President, Tilray Canada, stated, "Consumer demand is redefining what cannabis can be, and Tilray is leading that evolution through innovation that expands choice for adult consumers. As preferences move toward products that are discreet, convenient, precise, and smoke-free, ZONNA reflects our ability to anticipate where the category is going and deliver differentiated experiences that meet consumers there. By combining fast-acting Capsoil™ technology with a controlled-dose pouch, we are expanding choice, creating new occasions for cannabis consumption, and reinforcing Tilray’s leadership in bringing forward products that move the industry forward." Each ZONNA pouch contains 10 mg THC, providing a precise and controlled dose while eliminating much of the uncertainty associated with other consumption formats. The launch format includes 15 pouches per container (150 mg THC per pack) and features a child-resistant puck with separate compartments for unused and used pouches, supporting convenient and responsible disposal. ZONNA Bubble Pink THC Pouches are now available through licensed cannabis retailers across Canada where cannabis products are sold. Follow ZONNA on Instagram to stay up to date. Canadian cannabis products are produced and distributed by Aphria Inc., a licensed producer under the Cannabis Act. About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian and U.S. securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information, please contact: Tilray Brands Media: [email protected] Investors: [email protected] A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6c8a45a0-603f-44b6-9518-e6d056cb29d8
	Saved 2026-07-20 14:05 5d ago Published 2026-07-20 07:44 5d ago	Tilray oznámí výsledky 28. července Tilray Brands oznámí čtvrtletní výsledky 28. července. Půjde o výsledky za 4. čtvrtletí, které uzavírá fiskální rok 2026. Investoři sledují hlavně další zrychlení růstu tržeb a omezení velké ztráty. TLRY Tilray	FMP Stock News	72
Original source text Next week, on July 28, leading cannabis producer Tilray Brands (TLRY 0.58%) is scheduled to report its latest quarterly results. They'll be for its fourth quarter, wrapping up the company's 2026 fiscal year. That's always a big one for companies, as they may make major announcements and also provide guidance for the year ahead. If the results and news are encouraging, Tilray's stock may soar, leading to a rally in the weeks and months to follow. With the stock trading near its 52-week low, is it a good idea to buy Tilray Brands stock right now, before the company reports its latest results? Image source: Getty Images. If Tilray Brands' growth rate continues improving, that could be the catalyst the stock needs Tilray operates in a highly competitive Canadian cannabis market, where it's tough to grow its business while maintaining high margins. As a result, it has leaned heavily on acquisitions and on diversifying into other parts of the world, even into beverages, to grow its sales. The good news is that the company's growth rate has been improving in recent quarters and was back up to double digits in the third quarter. TLRY Revenue (Quarterly YoY Growth) data by YCharts If the cannabis company continues to show progress and its growth rate rises further in Q4, that may give investors renewed confidence that the business is going in the right direction. Tilray has struggled to prove it's a good buy, as over the past five years its value has fallen tremendously, by 97%. However, not only will Tilray need to show good top-line numbers, but its bottom line has been particularly troubling. While acquisitions can boost the top line, they can also add costs and lead to greater losses. In two of the past three fiscal years, Tilray incurred annual losses exceeding $1 billion, as it often incurs non-cash expenses and impairment charges. Avoiding another mammoth loss this fiscal year may be just as important as the company showing strong growth. Today's Change ( -0.58 %) $ -0.03 Current Price $ 4.28 Tilray's stock may seem cheap, but it's not a no-brainer buy Unfortunately, Tilray doesn't have a great track record of growing and staying out of the red. It has a lot to prove to growth investors, which is why buying the stock heading into Q4 would be a bit of a gamble. There are still plenty of concerns around the business, and no shortage of uncertainty. That's why a wait-and-see approach still makes the most sense, as despite its losses over the years, it wouldn't be surprising if Tilray's stock continued to decline after earnings.
	Saved 2026-07-09 21:17 16d ago Published 2026-07-09 16:00 16d ago	Tilray zahájila prodej léčebného konopí v Panamě Tilray Medical zahájila komerční prodej svého prvního léčebného konopí v Panamě. Produkt Tilray Oral Solution CBD100 bude dostupný na lékařský předpis prostřednictvím sítě Farmacias Arrocha. TLRY Tilray	FMP Stock News	78
Original source text PANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) and a leading global medical cannabis company, today announced the commercial launch of its first medical cannabis product in Panama, marking a significant milestone in the company’s ongoing global expansion and commitment to improving patient access to pharmaceutical-grade cannabinoid medicines worldwide. The launch follows the successful shipment of Tilray Oral Solution CBD100 from Tilray Medical’s EU-GMP-certified production facilities in Portugal through its joint venture with Solana Life Group S. de R.L. The product is intended to be distributed through Farmacias Arrocha, one of Panama’s leading pharmacy networks, where patients will be able to access Tilray Oral Solution CBD 100 under medical prescription. This is expected to provide patients and healthcare professionals with access to regulated, pharmaceutical-quality medical cannabis through established healthcare channels. The milestone reinforces Tilray Medical’s position as one of the most geographically diversified medical cannabis companies globally. Today, Tilray Medical serves patients across more than 20 countries spanning Europe, Australia, Canada, Latin America, and other emerging international markets, helping advance access to safe, high-quality cannabinoid-based medicines through regulated healthcare systems. Rajnish Ohri, President, International, Tilray Brands, stated, “At Tilray Medical, we believe every patient deserves access to safe, consistent, pharmaceutical-grade medical cannabis products. Our commercial launch in Panama reflects our broader vision to expand access to cannabinoid-based medicines through trusted healthcare systems around the world. As medical cannabis frameworks continue to advance, we are committed to working alongside healthcare providers, regulators, pharmacists, and patients to help shape the future of responsible access, advance medical education, and deliver high-quality treatment options that improve lives.” The launch supports Panama’s emerging medical cannabis framework established under Law 242 of 2021 and follows important regulatory advancements by the Ministry of Health, including Resolution No. 0406 of May 12, 2026, which established key requirements for patient access. The Ministry also recently introduced the Medical Cannabis Users and Authorized Caregivers Identification System (SIUCMAA), creating a structured pathway for physician authorization and patient registration. Manufactured in Portugal in accordance with rigorous European Union Good Manufacturing Practice (EU-GMP) standards, Tilray Oral Solution CBD100 is intended for use, where authorized, in patients with qualifying medical conditions authorized under Panamanian legislation. The product reflects Tilray Medical’s longstanding commitment to pharmaceutical quality, product consistency, patient safety, and regulatory compliance. Tilray Medical’s advanced cultivation and manufacturing facilities in Portugal serve as a strategic global export hub, supplying EU-GMP-certified medical cannabis products to regulated markets around the world. The platform enables Tilray Medical to efficiently support growing international demand while maintaining the highest pharmaceutical manufacturing standards across its global operations. The Panama launch represents another step in Tilray Medical’s broader strategy to expand access across Latin America, an emerging medical cannabis region. As governments across the region continue to establish regulatory pathways for cannabinoid-based medicines, Tilray Medical is well-positioned to support healthcare systems with trusted products, scientific expertise, and a proven track record of operating in highly regulated international markets. As global acceptance of medical cannabis continues to accelerate, Tilray Medical remains focused on advancing patient care, supporting clinical education, investing in research, and expanding access to high-quality medical cannabis products that help address unmet patient needs worldwide. For further information, please visit: www.Solana.pa About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, Tilray Medical Australia-New Zealand and Solana.pa in Panama. About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships, including the Company’s collaboration with Molteni to support the development of the Italian medical cannabis market. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information, please contact: Media: [email protected] Investors: [email protected]
	Saved 2026-07-07 23:45 18d ago Published 2026-07-07 19:00 18d ago	Tilray zůstává ztrátová, čisté tržby rostly jen mírně Tilray Brands je stále ztrátová: za devět měsíců do 28. února vzrostly čisté tržby jen o 6 % na 633,7 milionu USD, ale hrubý zisk klesl o 2 % a provozní ztráta činila 46,6 milionu USD. TLRY Tilray	FMP Stock News	72
Original source text Tilray Brands (TLRY 1.60%) is a leading cannabis company based in Canada that has been growing its operations all over the world. It's also expanded into beverages in a bid to diversify its operations and pursue even more growth opportunities. However, while the company has been growing over the years, it remains unprofitable. And many investors bought the cannabis stock in the hopes that it would one day be able to capitalize on opportunities in the U.S. if legalization takes place -- something that hasn't happened yet and may not happen anytime soon. This year, the marijuana stock is down more than 50%. It's a risky investment, but has its value gotten so low that it's worth buying despite the challenges it's facing? Image source: Getty Images. Tilray's business is getting bigger, but whether it's better is debatable Tilray has leaned on acquisitions to grow its business over the years, particularly as it has expanded its alcohol segment, but that isn't necessarily a surefire recipe for success. Acquisitions can be an easy way to generate more revenue, but there's also plenty of work involved to eliminate inefficiencies and unnecessary expenses, so they're accretive to the bottom line. The company's most recent financial results show that for the nine-month period ending Feb. 28, Tilray's net revenue rose by a fairly modest 6% year over year, totaling $633.7 million. However, despite the increase, its gross profit actually declined by 2% due to worsening margins. And the company incurred an operating loss of $46.6 million. With limited growth and no profitability, it's difficult to make the case that the stock is worth investing in, despite all of its acquisitions. Today's Change ( -1.60 %) $ -0.07 Current Price $ 4.31 The stock may look cheap, but that doesn't mean it's a good buy For investors who may be tempted to buy the dip on Tilray's stock, it may be worthwhile to look at the longer, five-year trajectory of the stock. During that longer time frame, the stock has plummeted a massive 97%. Time and time again, investors along the way were likely confident the stock had bottomed out and was destined to rally, only to leave them with significant losses and disappointment. When a stock has such troubling fundamentals and financials as Tilray, and its growth prospects are questionable, there's no magic price that suddenly makes it worth buying. The business needs to prove to investors that it's worth investing in, and Tilray is nowhere near that point. Simply acquiring more companies doesn't fix its problems. In fact, I'd argue it needs to get leaner and smaller, rather than larger and bloated, just to show growth. While it may look cheap right now, I wouldn't be surprised if it looks even cheaper in the future.
	Saved 2026-07-07 21:21 18d ago Published 2026-07-07 16:39 18d ago	Tilray v červnu klesla po vydání nových akcií a akvizici HelloMD Tilray v červnu klesla téměř o 19 % poté, co vydala nové akcie při swapu dluhu za akcie, snížil se jí cenový cíl a na konci měsíce oznámila akvizici HelloMD. TLRY Tilray	FMP Stock News	78
Original source text Tilray Brands (TLRY 1.60%) doesn't, to put it politely, have a history of pleasing its investors. That was well in evidence across June, as the company -- diversifying from its roots as a pure-play marijuana business -- fell into one of its more unattractive habits, announced a new acquisition, and saw an analyst cut his price target on the shares. The combination of these developments pushed Tilray's stock down by nearly 19% that month. New shares for old notes Over the course of its existence, the chronically loss-making Tilray has often issued new shares in order to bolster its finances. Sure enough, on two separate days in June -- one close to the start of the month, and one at the end -- the company divulged chunky stock flotations. It minted just over 1.2 million new shares in the first, and an additional 2.6 million-plus in the second. Image source: Getty Images. What makes the pair something of a departure for Tilray is that they weren't effected to raise capital. Instead, they were the equity side of a debt-for-equity swap the company effected with holders of some of its convertible notes (i.e., debt securities that convert to stock under certain conditions) that pay interest of 5.2%. As notes are booked as debt on the balance sheet, with this financial engineering move Tilray retired roughly $18 million in debt. That'll improve the balance sheet to a degree (the company had $284 million in long-term borrowings at the end of February) which is, of course, a positive development. What's not so positive is the pile of new shares, as one reason investors have been wary of Tilray is its frequent new share issues. At least the June pair isn't excessively dilutive; the company's outstanding share count topped 123 million. Later in the month an analyst following Tilray, Bernstein SocGen Group's Nadine Sarwat, cut her price target on the stock. She reduced it quite substantially, to $6.50 per share from $10. She also maintained her rather lukewarm stance on its future, keeping her market perform (hold, in other words) recommendation intact. On the second-to-last day of the month, Tilray announced its latest acquisition. It is now the owner of HelloMD, a telehealth and patient engagement company focused on medical cannabis. It didn't disclose the financial terms of the deal, but did say it boosts the company's "direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy." Today's Change ( -1.60 %) $ -0.07 Current Price $ 4.31 More losses to come? I think that combination of share price issuance and new asset acquisition is dismaying for some investors. I'd imagine they're wondering why Tilray is effectively reducing its stock's value while opening its wallet for an acquisition. That wouldn't be such a concern if the company showed signs of reversing its loss-making ways, but I'm not seeing much indication of this yet. Personally, I don't think this stock is a compelling buy right now.
	Saved 2026-06-29 21:46 26d ago Published 2026-06-29 17:09 26d ago	Tilray kupuje HelloMD, aby získala přímý přístup k pacientům Společnost Tilray Brands kupuje HelloMD, aby posílila přímý přístup k pacientům a vytvořila plně vertikálně integrovaný ekosystém lékařského konopí v Kanadě. Akvizice rozšíří digitální zdravotní platformu a podporu pacientů. TLRY Tilray	FMP Stock News	86
Original source text NEW YORK and TORONTO, June 29, 2026 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (NASDAQ: TLRY; TSX: TLRY) (“Tilray”), a global leader in medical cannabis, today announced the acquisition of HelloMD Corporation, a digital healthcare and patient engagement platform that expands Tilray’s direct-to-patient capabilities, creates a fully vertically integrated medical cannabis framework for Tilray in Canada, and advances its global medical cannabis growth strategy. Tilray was the successful bidder in HelloMD’s formal sale process and plans to acquire HelloMD’s Canadian medical cannabis assets following formal Court approval on June 29, 2026. The acquisition will strengthen Tilray’s global medical cannabis platform by expanding direct-to-patient capabilities, enhancing physician and patient education, and deepening engagement across the care journey, while establishing an integrated Canadian framework that connects quality cultivation, clinical expertise, practitioner support, product access, and fulfillment. As medical cannabis becomes a more established part of healthcare, Tilray is building an integrated care model that supports patients from education and physician consultations to product access, fulfillment, and ongoing support. Historically, medical cannabis has often been considered later in a patient’s care journey. With the appropriate resources and clinical support, HelloMD provides Tilray with a platform to help engage eligible patients earlier through education, practitioner access, and trusted guidance, expanding awareness of regulated, plant-based medical cannabis options as part of a broader approach to natural health and wellness. HelloMD has supported hundreds of thousands of patients through telehealth consultations, educational resources, and personalized medical cannabis guidance. Its platform complements Tilray’s global healthcare infrastructure, including EU-GMP certified cultivation and manufacturing, pharmaceutical distribution through CC Pharma, medical cannabis clinics, digital pharmacy capabilities, and patient access platforms across North America, Europe, Australia, and other international markets. Blair MacNeil, President, Tilray Canada, said, “Medical cannabis is becoming a more integrated part of healthcare, and patients are looking for trusted, convenient access to care supported by education and guidance. By combining HelloMD’s digital healthcare platform with Tilray’s medical cannabis portfolio, clinical expertise, and national fulfillment capabilities, we are creating a more connected pathway for patients and healthcare practitioners in Canada. This acquisition establishes a fully vertically integrated medical cannabis framework for Tilray in Canada while strengthening our broader global platform, expanding patient engagement, practitioner support, and access in regulated medical markets. As adoption continues to grow, Tilray is well positioned to serve patients with high-quality medical cannabis solutions and healthcare services across the continuum of care.” Larry Lisser, CEO, HelloMD, added, “From day one, our mission at HelloMD has been to make medical cannabis more accessible through innovative technology, approachable education, and trusted healthcare experiences. I’m incredibly proud of what our team built alongside our healthcare practitioners and business partners, and of how we scaled together to deliver meaningful outcomes for patients. I believe Tilray has the expertise, infrastructure, and drive to expand the platform’s reach and impact, benefiting patients for years to come.” The acquisition is expected to enhance Tilray’s ability to deliver a more seamless patient experience, generate insights that support education and engagement, and expand access in regulated medical markets globally. Tilray also sees an opportunity to broaden patient and consumer awareness in adjacent wellness categories, including sleep support and pain management, where over-the-counter products represent a multi-billion-dollar market in which Tilray is not meaningfully represented today. Subject to applicable regulations, Tilray intends to use HelloMD’s digital education and engagement capabilities to responsibly build awareness of regulated, plant-based medical cannabis alternatives among appropriate audiences seeking natural health solutions. The acquisition reinforces Tilray’s commitment to advancing medical cannabis through innovation, patient engagement, scientific leadership, expanded global access, and the continued strengthening of HelloMD Corporation’s existing strategic partnerships to ensure continuity of care and sustained value for patients and healthcare practitioners. As Tilray grows its international medical business, the Company remains focused on delivering high-quality medical cannabis products and healthcare solutions to patients worldwide. Financial terms of the transaction were not disclosed. About HelloMD HelloMD Corporation is a leading digital healthcare and patient engagement platform focused on medical cannabis education, physician consultations, and patient support services. Through its technology-driven approach, HelloMD helps patients navigate medical cannabis treatment with confidence and access trusted healthcare resources. About Tilray Medical Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray Medical, Good Supply, Redecan, ARX, and Broken Coast. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers, and governments, in 20 countries and across five continents. For more information on Tilray Medical, visit Tilray Medical Europe, Tilray Medical Canada, and Tilray Medical Australia-New Zealand. About Tilray Brands Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray’s mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray’s unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and craft beverages. For more information on how we are elevating lives through moments of connection, visit Tilray.com and follow @Tilray on all social platforms. Forward-Looking Statements Certain statements in this communication that are not historical facts constitute forward-looking information or forward-looking statements (together, “forward-looking statements”) under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. Forward-looking statements can be identified by words such as “forecast,” “future,” “should,” “could,” “enable,” “potential,” “contemplate,” “believe,” “anticipate,” “estimate,” “plan,” “expect,” “intend,” “may,” “project,” “will,” “would” and the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Certain material factors, estimates, goals, projections, or assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this communication. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company’s ability to commercialize new and innovative products worldwide. Many factors could cause actual results, performance, or achievement to be materially different from any forward-looking statements, and other risks and uncertainties not presently known to the Company or that the Company deems immaterial could also cause actual results or events to differ materially from those expressed in the forward-looking statements contained herein. Forward‑looking statements in this communication also include statements regarding the Company’s market positioning, ability to meet evolving medical cannabis demand in regulated pharmaceutical environments, and expectations concerning the effectiveness of strategic partnerships. For a more detailed discussion of these risks and other factors, see the most recently filed annual information form of Tilray and the Annual Report on Form 10-K (and other periodic reports filed with the SEC) of Tilray made with the SEC and available on EDGAR. The forward-looking statements included in this communication are made as of the date of this communication and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events, or otherwise unless required by applicable securities laws. For further information, please contact: Media: [email protected] Investors: [email protected]